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Abstract
Hashimoto’s Thyroiditis (HT) is one of the most common autoimmune diseases (Hiromatsu et al. 2013 p.13). It primarily affects
the thyroid gland. The thyroid gland influences growth and regulates the body’s metabolism by manipulating hormonal levels.
Hashimoto’s thyroiditis affects thyroid function through mechanisms that cause the hormone levels to become dysregulated.
The standard therapy for Hashimoto’s thyroiditis is hormone replacement. This approach helps most patients by regulating their
thyroid hormones, though there are some individuals who fail treatment. Untreatable patients are plagued with weight gain, sleep
disturbances, and other symptoms. Certain factors in thyroid disease may cause various secondary complications including psychiatric manifestations. Research into these patients has shown that the removal of the thyroid gland seems to improve their clinical
condition. Therefore, in the situation when significant symptoms remain after what appears to be adequate medicinal treatment,
the possibility of surgery should be entertained. This review discusses the pathological underpinnings of Hashimoto’s disease and
reviews some of the published literature from the past ten years in relation to the treatment of HT.
Introduction
The thyroid gland is a butterfly-shaped endocrine gland
found in the lower front portion of the neck. The thyroid primarily controls metabolic function. This includes
hormone production, growth, and bodily maturation.
Thermoregulation, as well as brain maturation and other
cognitive functions, are also controlled by the thyroid
(Drake 2018). Thyroid dysfunction can be due to hyperthyroidism, the overproduction of thyroid hormone, or
hypothyroidism, which is the underproduction of hormones. The most common symptoms of hyperthyroidism
are weight loss and palpitations, while the most common
symptoms of hypothyroidism are weight gain and lethargy
(Guyton, Hall 2006 Pp. 938-940).
According to the American Thyroid Association (ATA),
there are approximately twenty-million people in the
United States who suffer from thyroid disease. Of this
twenty-million, about fourteen million of them suffer from
an autoimmune condition known as Hashimoto’s thyroiditis (American Thyroid Association, General Information).
An autoimmune disease develops when the body’s immune
system begins attacking its own organs or particular proteins. Autoimmune diseases are caused by autoantibodies, which respond to normal organs as foreign invaders.
Hashimoto’s Thyroiditis occurs when the body attacks
either the thyroid cells or their product thyroxine.
Hashimoto’s Thyroiditis can develop in patients with
either a genetic or environmental susceptibility (Pyzik
et al. 2015). Hiromatsu et al. studied some of the current concepts of genetic susceptibility to Hashimoto’s
Thyroiditis. They noted that, specifically, the concordance
rate for HT in identical twins (monozygotic) is 55%, while
in non-identical twins (dizygotic) it is 0%. Moreover, they
also observed that there is a higher rate of concordance of
thyroid autoantibodies not associated with Hashimoto’s
Thyroiditis in monozygotic twins than in dizygotic twins.
In these siblings, 80% of monozygotic twins had autoantibodies versus 40% in nonidentical twins (Hiromatsu et al.
2013). This study concluded that genetics is a significant
factor in HT.
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Several genetic loci have also been identified as associated with Hashimoto’s thyroiditis, most notably multiple
human leukocyte antigen-DR (HLA-DR) isotopes. HLADR is a lymphocyte surface receptor. When genetically
altered it affects what is presented to the T-cells which
elicits an immunologic response. This response can influence the selectivity and binding of peptides, which appears to predispose individuals to the development of
HT (Hiromatsu et al. 2013). Other immune modulators
released from the lymphocytes, such as interferon-gamma
can also instigate the development of HT.
Environmental triggers that affect individuals susceptible to Hashimoto’s thyroiditis include infections, dietary
factors, and pregnancy. Although iodine deficiency can
cause thyroid diseases, excess iodine can induce autoimmunity by increasing the body’s sensitivity to abnormal
thyroglobulin. Thyroglobulin is the protein produced by
the thyroid and is the precursor to the thyroid hormones
triiodothyronine (T3) and thyroxine (T4). In the presence of excess iodine, thyroglobulin can be abnormally
iodinated. This can lead to the production of autoantibodies as well as to the toxicity of the thyroid cells and
hypothyroidism (Hiromatsu et al. 2013).
With all this in mind, the two main autoantibodies
linked to Hashimoto’s Thyroiditis are anti-thyroglobulin
and antithyroid peroxidase. An anti-thyroglobulin antibody binds to thyroglobulin which limits availability and
subsequent release of T3 and T4 thyroid hormones. The
thyroglobulin directly affects the functional aspect of the
thyroid and its reduction, or absence contributes to a
patient’s hypothyroid symptoms. Antithyroid peroxidase,
on the other hand, targets thyroid follicular cells or thyrocytes. The way it does this is by tagging the thyroid
cells for destruction which can in turn lead to hypothyroidism. HT is an insidious disease that can take years
before becoming clinically significant (Guyon, Hall 2006,
Pp. 940-943).
Many patients eventually require treatment with thyroid hormone replacement. This therapy involves being
prescribed a bio-identical thyroid hormone medication,
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such as Levothyroxine also known as Synthroid or Armor
Thyroid. For most patients, the treatment works well,
and the symptoms are resolved. There are circumstances
though where hormone replacement fails and in cases
like these clinical research has shown that the surgical
excision of the thyroid or thyroidectomy should be considered. This potentially works because it reduces the antibody load and the antibody’s potential effects on other
targets (Goldvog et al. 2019, p. 462). The main objective
of this paper is to review the possible solutions to treatment-resistant Hashimoto’s thyroiditis disease.
Methods
Data was collected through Touro College’s online library using several scientific scholarly databases such
as ProQuest and PubMed databases. The key-phrases
used were Hashimoto’s Disease, Hashimoto’s thyroiditis, thyroidectomy, and autoimmune thyroiditis. Only
peer-reviewed journals and English language articles were
analyzed.
Discussion
Autoimmune thyroid disease was first described in 1912
by the Japanese surgeon Hakaru Hashimoto (Pyzik et al.
2015). He identified a cohort of patients with lymphoid
infiltration of the thyroid with associated destruction of
the thyroid glands which he called “struma lymphomatosa” (Hiromatsu et al. 2013). The concept of autoimmune
diseases was not recognized until the 1950s and even
currently many of these diseases are not fully understood.
Hypothyroidism is diagnosed by a thyroid function blood
test that shows elevated thyroid stimulating hormone

Table1: Diagnostic scheme (Chaker et al. 2017)

(TSH) which reflects a reduction in the thyroid’s function
(Drake 2018). Unlike many other diseases, patients who
suffer from hypothyroidism do not exhibit symptoms
over a set timeline. Some patients develop their symptoms over days to months, while for others, symptoms
evolve over years to decades (Lee 2020). In other words,
hypothyroidism can exist in many states which can range
from a subclinical harmless state to a significant clinical
presentation (Chaker et al. 2017). Table 1 shows a flow
chart on the process of diagnosing the disease.
There is controversy as to when medical professionals
should start treating patients with clinical hypothyroidism. According to the American Association of Clinical
Endocrinology (AACE) guidelines, there are a few opinions as to when treatment commences. Treatment generally relies on the Thyroid Stimulating Hormone (TSH)
level.TSH responds to feedback inhibition of the pituitary
gland, the organ which produces TSH. As the levels of thyroid hormone increase, the TSH decreases, and as the
levels of thyroid hormone decrease the TSH increases.
This is an example of a negative feedback loop (Guyon,
Hall 2006, p. 939). The American Thyroid Association’s
guidelines suggest that when the TSH levels approach 10
mIU/L patients are clinically hypothyroid and need treatment. Others claim that there are therapeutic reasons
to start treating at lower levels. Regardless, treatment
is always dependent on the clinical symptoms being addressed (Garber et al. 2012, p. 1112).
The most common symptoms of hypothyroidism in
adults are weight gain, fatigue, hot/cold intolerance, and
memory loss (brain fog). Table 2 lists the signs and symptoms related to hypothyroidism. The symptoms for the
diagnosis of hypothyroidism are reflective of the hormonal insufficiency in different organs (Carle et al. 2014, p.
593). Symptoms vary by age and health status.An increase
in the severity of symptoms may predict a harsher course
of hypothyroidism. Clinical symptoms were originally
used to diagnose hypothyroidism. A variety of outdated
scoring systems such as the Billewicz score system and
the Zulewski score system were utilized.With the advent
of a sensitive blood test for TSH, these systems have been
phased out and the fluctuation in TSH levels is what is
used to guide the treatment of the disease.
Thyroid function has also been proven to play a crucial role in the cognitive development of youth and
many other facets regulating nervous system activity.
Neuropsychiatric symptoms refer to a gamut of emotional and cognitive complications that are directly related to alterations in the brain (Dickerman, Barnhill
2012). Due to the close association between thyroid and
the nervous system function, disturbances in the body’s
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metabolic state can be related to a range of neurological signs and symptoms. These signs include headaches,
mood, and cognitive disorders, ophthalmoplegia (eye
movement disorder), tremors, and muscle weakness.
Hypothyroidism can cause psychiatric symptoms such as
depression, anxiety, memory deficits, and even psychosis.
According to medical guidelines, testing for thyroid disease is a case-by-case decision, but patients who present
with psychiatric issues should all be screened for thyroid
dysfunction (Dickerman, Barnhill 2012, p.130).
In the neuropsychiatric realm, a sudden worsening in a
patient’s hypothyroidism may result in myxoedema coma,
a life-threatening condition that is also associated with a
rapid decline in mental health. The degree to which subclinical hypothyroidism and mild hypothyroidism impacts
moods and cognitive functions, as well as whether these
symptoms respond to treatment, remains controversial
(Stasiolek 2015). A case study reported a 61-year-old
woman who first presented to the emergency room
complaining of severe chronic daily headaches. According
to the patient, the headaches started 9 months prior and
were described as, “bi-lateral with pressing-type quality,
without associated symptoms such as nausea, photophobia, and did not worsen with exercise,”. The patient also
presented with depressive symptoms which were evaluated by a psychiatrist. The woman was subsequently diagnosed as having depressive syndrome. She was prescribed
antidepressants but the medication failed to correct the
problem. The patient later had a full medical evaluation
which included blood work. The blood work revealed
an increased anti-TPO antibody titer. This patient was
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diagnosed with encephalopathy related to autoimmune
thyroid disease, which is also known as Hashimoto’s encephalopathy (Correia et al. 2019).
Another physical ailment associated with hypothyroidism is reduced cardiac output. This is a result of the relaxation of vascular smooth muscle tissue. This relaxation
occurs because the thyroid hormones which control
the pacemaker-related genes reduce the heart rate and
cardiac output which subsequently increases arterial stiffness leading to hypertension. (Udovcic et al. 2017, p. 55).
Because of this process, a person’s heart rate will elevate
in the presence of excess thyroid hormone (hyperthyroidism) or reduce if the person has less thyroid hormone
present (hypothyroidism). The change from normal levels
to abnormal levels produces a domino effect of increased
arterial stiffness, which then causes increased systemic
vascular resistance. A variety of medicinal conditions can
arise due to these changes which include atrial fibrillation
and heart failure (Udovcic et al. 2017).
Thyroid dysfunction can also be associated with
changes in body temperature and body weight. The thyroid-stimulating hormone regulates the basal metabolism,
thermogenesis, and lipid glucose metabolism (Sanyal,
Raychaudhuri 2016). “According to the National Health
and Nutrition Examination Survey, obesity affected 32.2%
of adults in 2003–2004.” (Biondi 2010, p. 3614). A study
performed in India at the Medwin Hospital’s department
of Endocrinology and Obesity Clinic found that thyroid
dysfunction was realized more in individuals that were
obese. All the patients included in the study underwent
a physical examination which included, “Height, weight,
waist circumference, presence of goiter, acanthosis nigricans or peripheral stigmata of dyslipidemia and blood
pressure measurement,” (Verma et al. 2008). Their study
consisted of a total of 1075 patients. The study was divided into two subgroups. One group was made up of 625
patients who were enrolled in the hypothyroidism clinic,
and the other group was 450 patients who were enrolled
in the obesity clinic. Of the patients from the hypothyroidism clinic, 44% of them found that their body mass
index (BMI) was greater than 25 kg/m2 with the typical
BMI for a healthy person being anywhere between 18.5
and 24.9 kg/m2. Of the patients from the obesity clinic,
only 33% had hypothyroidism (Verma et al. 2008). They
concluded that most people who suffer from hypothyroidism have the likelihood of being obese.
Thyroid glands are also prone to develop nodules
known as goiters. A goiter refers to an abnormal enlargement within the thyroid gland. It is important to stress
that the majority of people that have goiters do not have
any thyroid gland dysfunction. People with Hashimoto’s
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thyroiditis, however, seem to have more nodules than the
average person. This leads to patients with Hashimoto
thyroiditis having a slightly higher risk of developing thyroid cancer (Fish 2019 p.334). Some researchers say that
the higher rate for papillary thyroid carcinoma is due to
the presence of an autoimmune-response, or possibly
anti-tumor immune response to the immune mediators
(Graceffa et al. 2019, p.5).
As mentioned previously in this paper, the primary
treatment for Hashimoto’s disease consists of hormone
replacement. Hormone replacement aims to balance the
patient’s biochemical system.While taking out the thyroid
might prevent an antibody response, if a patient does not
have a significant quality of life issue, doctors would not
suggest having a total thyroidectomy (Promberger et al.
2014, p. 979). There are cases in which a patient is still
affected by the symptoms of hypothyroidism, even after
taking the correct dosage of medication and correcting
the abnormal TSH level. In that instance, doctors might
suggest that the patient undergo a total thyroidectomy
(Pollock et al. 2001, p.894).
There are some standard indications as to when it is
appropriate to have a thyroidectomy beyond having thyroid cancer. When a patient starts to exhibit compressive
symptoms such as discomfort while swallowing, the feeling
of strangulation, or tightness in the neck, it is appropriate
to surgically remove the thyroid gland (Pradeep et al. 2011).
Greater than 63% of patients with HT identified with the
symptom of compression (McManus et al. 2011, p. 336).
Another symptom that hormone replacement cannot cure
is painful Hashimoto thyroiditis. Painful HT is also known
as acute exacerbation of HT. This condition is not very
common and in most instances is treated adequately with
painkillers. Having a total thyroidectomy is thought to be
the best treatment for this condition especially when painkillers do not provide relief (Peng et al. 2020, p.12).
In certain instances, patients with Hashimoto’s disease
may not necessarily experience a resolution of their complaints with medication. A study of 426 women who were
all planning on having their thyroids removed for various
reasons including HT. Before surgery, they all answered
the SF-36 questionnaire, which is a set of generic, and easily administered quality-of-life measurements. The results
established that patients who had high anti-TPO levels
had lower quality of life measures even though they were
taking the correct dosage of medication based on their
TSH levels (Ott et al. 2011, p.165).
In the Annals of Internal Medicine, Guldvog et al., who
performed the first randomized controlled trial, demonstrated that the removal of the thyroid gland in patients
with histologically verified Hashimoto’s disease can

improve their quality of life by normalizing their anti-TPO
antibody titer levels.This study was performed on patients
between the ages of 18 to 79 years. They all had anti-TPO
titers above 1000 IU/ml (normally less than 35 IU/ml). In
total there were 150 test subjects all of whom had persistent Hashimoto-related symptoms. Before the data was
collected and the surgery was performed, all the patients
were monitored for thyroid function until they achieved
euthyroid status or normal thyroid function. Participants
were either assigned to undergo total thyroidectomy with
continued hormone replacement or to only receive hormone replacement therapy. After 18 months, the anti-TPO
levels of the surgical group had fallen from a mean of 2232
IU/ml to 152 IU/ml, and the general health score of the
surgical group improved from 38 to 64 points.The chronic
fatigue frequency in the surgical group decreased from 82%
to 35% of the individuals. The overall score was improved
compared to the original SF-36 questionnaire. The control
group showed no significant changes. The researchers hypothesized that the improvement in symptoms could be
related to the normalization of serum anti-TPO antibody
titers. (Goldvog et al. 2019).
Dr. Trevor Angell interpreted and reviewed the study
done by Guldvog et al. and concluded that the results
were compelling. Guldvog et al. indicates that patients
with Hashimoto’s thyroiditis might have persistent symptoms due to more than just the thyroid dysfunction. They
found that a thyroidectomy may modulate the immune
response by removing the antigen and thereby reducing
the inflammation and the inflammatory mediators. With
the removal, the symptoms caused by HT would subsequently be alleviated (Angell 2019, p.180).
Nevertheless, the initial plan of treatment for patients
who have the symptoms of hypothyroidism should be
supplemental hormone replacement. In the case when
patients do not respond positively to hormone replacement, a total thyroidectomy has proven to be effective
as well. For a patient that chooses to have surgery, a
risk analysis of surgical complications must be evaluated.
One study predicted that if more people start removing
their thyroids then complications will increase 12-fold.
This rate, according to the literature, would change from
3.05% to 36.6% (Memeh et al. 2020).
Conclusion
In conclusion, not every person who has Hashimoto’s
thyroiditis should have thyroid surgery. According to the
research reviewed, having a thyroidectomy might only
be recommended to patients who have Hashimoto’s
Thyroiditis and who are experiencing neuropsychiatric
symptoms after their TSH levels are stabilized. There
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needs to be more research evaluating and specifying the
benefits of having a thyroidectomy. Larger test groups
need to be observed, and the follow-up period should be
extended. Though they are not frequent, complications of
total thyroidectomy are real, and the risk-benefit ratio
must be assessed on a case by case basis.
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